Morepen Laboratories Limited

NSEI:MOREPENLAB Stock Report

Market Cap: ₹25.6b

Morepen Laboratories Past Earnings Performance

Past criteria checks 5/6

Morepen Laboratories has been growing earnings at an average annual rate of 11.4%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 15.8% per year. Morepen Laboratories's return on equity is 9.7%, and it has net margins of 4.6%.

Key information

11.4%

Earnings growth rate

9.5%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate15.8%
Return on equity9.7%
Net Margin4.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Apr 23
Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Nov 23
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Aug 10
Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 21
Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Apr 05
Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Sep 14
Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

May 21
Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?

Mar 12
Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?

Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay

Feb 22
Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay

Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 07
Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Jan 21
Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Jan 03
Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Dec 16
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Nov 28
Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Could The Morepen Laboratories Limited (NSE:MOREPENLAB) Ownership Structure Tell Us Something Useful?

Nov 09
Could The Morepen Laboratories Limited (NSE:MOREPENLAB) Ownership Structure Tell Us Something Useful?

Can You Imagine How Morepen Laboratories' (NSE:MOREPENLAB) Shareholders Feel About The 75% Share Price Increase?

Oct 13
Can You Imagine How Morepen Laboratories' (NSE:MOREPENLAB) Shareholders Feel About The 75% Share Price Increase?

Morepen Laboratories Limited's (NSE:MOREPENLAB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Sep 17
Morepen Laboratories Limited's (NSE:MOREPENLAB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Morepen Laboratories Limited's (NSE:MOREPENLAB) Earnings Haven't Escaped The Attention Of Investors

Aug 26
Morepen Laboratories Limited's (NSE:MOREPENLAB) Earnings Haven't Escaped The Attention Of Investors

Is Now The Time To Put Morepen Laboratories (NSE:MOREPENLAB) On Your Watchlist?

Aug 19
Is Now The Time To Put Morepen Laboratories (NSE:MOREPENLAB) On Your Watchlist?

We Think Morepen Laboratories (NSE:MOREPENLAB) Can Stay On Top Of Its Debt

Jul 29
We Think Morepen Laboratories (NSE:MOREPENLAB) Can Stay On Top Of Its Debt

Update: Morepen Laboratories (NSE:MOREPENLAB) Stock Gained 80% In The Last Five Years

Jul 08
Update: Morepen Laboratories (NSE:MOREPENLAB) Stock Gained 80% In The Last Five Years

Revenue & Expenses Breakdown
Beta

How Morepen Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:MOREPENLAB Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2316,4227612,1270
30 Sep 2315,4335311,9580
30 Jun 2315,2384772,8840
31 Mar 2314,2203871,6540
31 Dec 2214,2704281,8000
30 Sep 2214,7655531,8430
30 Jun 2214,7217682,6040
31 Mar 2215,5581,0171,7240
31 Dec 2114,7431,1611,8090
30 Sep 2113,8541,1841,5890
30 Jun 2113,2951,0822,0920
31 Mar 2111,9809711,4070
31 Dec 2011,1368141,3450
30 Sep 2010,3806841,2790
30 Jun 209,1834531,6780
31 Mar 208,5843361,1430
31 Dec 198,7313311,1610
30 Sep 198,5303121,1180
30 Jun 198,1173401,4740
31 Mar 197,7142889950
31 Dec 187,2582529800
30 Sep 186,6722678790
30 Jun 186,4363088410
31 Mar 186,1012968070
31 Mar 175,9912367390
31 Mar 164,8611286160
31 Mar 154,014215170
31 Mar 143,670-288074

Quality Earnings: MOREPENLAB has high quality earnings.

Growing Profit Margin: MOREPENLAB's current net profit margins (4.6%) are higher than last year (3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MOREPENLAB's earnings have grown by 11.4% per year over the past 5 years.

Accelerating Growth: MOREPENLAB's earnings growth over the past year (78%) exceeds its 5-year average (11.4% per year).

Earnings vs Industry: MOREPENLAB earnings growth over the past year (78%) exceeded the Pharmaceuticals industry 23.1%.


Return on Equity

High ROE: MOREPENLAB's Return on Equity (9.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.